Information Provided By:
Fly News Breaks for August 6, 2015
CELG, XNPT
Aug 6, 2015 | 08:26 EDT
After meeting with a psoriasis doctor, RBC says that the company's '829 drug could be superior to Celgene's (CELG) Otezla as a treatment for psoriasis and potentially MS. The firm believes that the stock is cheap, and says that the company has a "reasonable" chance to become a takeover target. RBC keeps a $10 price target and Outperform rating on Xenoport.
News For XNPT;CELG From the Last 2 Days
There are no results for your query XNPT;CELG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.